IMW 2021 | MASTER trial: Dara-KRD, ASCT & MRD-directed therapy in myeloma
Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, Birmingham, AL, gives an overview of the findings of the MASTER study (NCT03224507) investigating daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd), autologous stem cell transplant (ASCT), and measurable residual disease (MRD) response-adapted treatment for newly diagnosed multiple myeloma. The study used MRD, assessed by next generation sequencing, to guide the use and duration of Dara-KRd after ASCT and the cessation of treatment in patients who achieved MRD negativity. 123 patients were treated in the study. At a median follow-up of 25.1 months it was reported that 80% of patients had achieved MRD negativity and it was concluded that MRD-directed adaptive therapy may be a viable option in the treatment of myeloma as an alternative to indefinite maintenance. Dr Costa discusses these findings and talks on the impacts of different cytogenetic abnormalities on outcomes in the trial. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
